SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) senior management will host a conference call and live audio webcast on Thursday, October 27, 2011 at 9 a.m. ET to discuss the Company’s third quarter 2011 financial and operational results. The webcast will be available in the investor relations section of the Company’s Web site at www.celgene.com.
Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of novel therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit the Company’s Web site at www.celgene.com.
This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts. Forward-looking statements generally are identified by the words "expects," "anticipates," "believes," "intends," "estimates," "aims," "plans," "will," "will continue," "seeks," “outlook” and similar expressions. Forward-looking statements are based on current plans, estimates, assumptions and projections, and therefore you should not place too much reliance on them. Forward-looking statements speak only as of the date they are made, and we undertake no obligation to update any forward-looking statement in light of new information or future events, although we intend to continue to meet our ongoing disclosure obligations under applicable laws. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. We caution you that actual results or outcomes may differ materially from those expressed in, or implied by, the forward-looking statements as a result of the impact of a number of important factors, as well as other known and unknown risks and uncertainties, or if the assumptions underlying any of these statements prove incorrect. Certain of these factors are discussed in more detail in our Annual Report on Form 10-K filed with the Securities and Exchange Commission.
Jacqualyn Fouse, 908-673-9956
Senior Vice President and Chief Financial Officer
Patrick E. Flanigan III, 908-673-9969
Vice President, Investor Relations
KEYWORDS: United States North America New Jersey
INDUSTRY KEYWORDS: Health Biotechnology Genetics Oncology Pharmaceutical Professional Services Banking Finance